Year: 2021

Dublin Office Named as One of Ireland’s Best Workplaces SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) — Udemy (Nasdaq: UDMY), a leading destination for learning and teaching online, today announced that it has been officially certified as a Great Place to Work in Ireland. After a thorough and independent analysis conducted by Great Place to Work® Institute Ireland, Udemy was found to be one of Ireland’s Best Workplaces 2021. Great Place to Work® Ireland is the global authority on high-trust, high-performance workplace cultures. The accreditation process is based on direct feedback from employees, provided as part of an extensive and anonymous survey about the workplace experience. “As we continue to grow and invest in our team in Ireland, we’re honoured to be recognized as an employer of choice in an increasingly competitive...

 Press ReleaseNicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in GlaucomaDenali Phase 3 co-funded equally by Nicox and Ocumension Therapeutics Phase 3 program supports submission of both U.S. and China NDAsDecember 16, 2021 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the first patient has been screened in China in the ongoing Denali Phase 3 clinical trial, opening the way for New Drug Application (NDA) submissions in both the United States (U.S.) and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, which also includes a long-term safety extension, has been recruiting patients in the U.S. since November 2020. Approximately 670 patients are...

         Helexia, a distributed-generation and energy-efficiency specialist, has won an additional 27 megawatts of photovoltaic capacity for the Vivo cell phone network, a Telefonica brand. Helexia is a subsidiary of Voltalia (ISIN code Euronext Paris: FR0011995588), an international player in renewable energies. Following the August 31 launch of the construction of 17 solar photovoltaic (PV) units to power the facilities of Vivo, a subsidiary of the Telefonica Group in Brazil, Helexia is adding 8 units totalling 27 megawatts to this 20-year contract. Initially planned for 60 megawatts, the capacity is therefore increased to 87 megawatts, turning Helexia as leading Solar PV supplier of Distributed Energy Ressources (DER) to Telefonica in Brazil. The additional units will be located in the states of Amazonas, Tocantins, Sao Paulo and Rio...

Initial results show excellent immune response after third dose of VLA2001 administered 7 to 8 months after the second dose of primary vaccination Antibody titers increased 42- to 106-fold two weeks after booster dose vs pre-booster levels Antibody titers four-fold higher compared to two weeks after primary immunization Evaluating sera from boosted participants for cross-neutralization against Variants Of Concern, including OmicronSaint Herblain (France), December 16, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive homologous booster data from the Phase 1/2 study, of its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001. Initial results confirm that VLA2001 significantly boosted immunity in participants who received VLA2001 as a primary vaccination. 77 of the 153...

Amsterdam, 16 December 2021 – Today, a consortium that consists of Arcadis (EURONEXT: ARCAD), the leading global Design & Consultancy organization for natural and built assets, research and consultancy firm Berenschot and urban design agency PosadMaxwan, announces that it has won all five framework contracts for policy consultancy and engineering services for the Dutch Ministry of Infrastructure and Water Management. The Ministry estimates that the combined value of the contracts is approximately €37.5 million per year. The duration of the contracts is two years, with the possibility of extending it twice for one year each. The five framework contracts closely align to the priorities of the Dutch Government and are focused on the following themes: sustainable mobility and climate-resilient infrastructure; sustainable, healthy and...

Ad hoc announcement pursuant to Art. 53 LRShare buyback of up to USD 15bn planned to be executed by end 2023, highlighting confidence in top line growth and deep pipelineSales expected to grow 4%+ CAGR through 2026* and up to 20 new assets with significant sales potential set to potentially be approved by 2026, to fuel further growth through 2030 and beyondCapital allocation strategy aims to combine investing in core business and returning excess capital to shareholdersIncrease of CHF 10bn to the current share buyback authority to be sought at forthcoming Annual General Meeting on March 4, 2022Basel, December 16, 2021 — Novartis today announced that it will initiate a share buyback of up to USD 15 billion to be executed by the end of 2023. The buyback is funded through the proceeds from the recent sale of 53.3 million Roche...

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 16 December 2021: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, was notified on 14 December 2021 that the Company’s Employee Benefit Trust (“EBT”) intends to subscribe for 1,145,472 new ordinary shares in the Company at their par value of 2p each and at an aggregate cost to the EBT of £22,909.44. (“New Ordinary Shares”). The Company has agreed to lend £22,909.44 to the...

Ad hoc announcement pursuant to Art. 53 LRShare buyback of up to USD 15bn planned to be executed by end 2023, highlighting confidence in top line growth and deep pipelineSales expected to grow 4%+ CAGR through 2026* and up to 20 new assets with significant sales potential set to potentially be approved by 2026, to fuel further growth through 2030 and beyondCapital allocation strategy aims to combine investing in core business and returning excess capital to shareholdersBasel, December 16, 2021 — Novartis today announced that it will initiate a share buyback of up to USD 15 billion to be executed by the end of 2023. The buyback is funded through the proceeds from the recent sale of 53.3 million Roche bearer shares. The Novartis Board of Directors and Executive Committee are confident in the company’s short, medium and long-term...